| Elena Garcia, MD | |
|
503 Medical Center Blvd, Ste 100, Conroe, TX 77304-2809 | |
| (936) 788-1060 | |
| (936) 788-2844 |
| Full Name | Elena Garcia |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 26 Years |
| Location | 503 Medical Center Blvd, Conroe, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750375150 | NPI | - | NPPES |
| 080191575 | Other | TX | RAILROAD MEDICARE |
| 150961401 | Medicaid | TX | |
| 037714502 | Medicaid | TX | |
| 8G0690 | Other | TX | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | L1050 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Aspire Behavioral Health Of Conroe, Llc | Conroe, TX | Hospital |
| Hca Houston Healthcare Conroe | Conroe, TX | Hospital |
| Memorial Hermann Hospital System | Houston, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Affiliates Of Family Medicine Inc | 3779528005 | 8 |
News Archive
Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has granted Ventana Medical Systems, Inc., a worldwide non-exclusive license to CST patent rights and proprietary antibody reagents relating to the detection of epidermal growth factor receptor mutations for the field of tissue-based in vitro diagnostic testing.
Valley Presbyterian Hospital was awarded a $772,643 grant from First 5 LA to implement the 'Welcome Baby' prenatal and infant care program. The grant period is from December 1, 2013 through June 30, 2014 and is expected to be extended for an additional year, through June 30, 2015.
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
In a publication in the scientific journal, Nature, a team at CAMBIA in Canberra unveils the 'kernel' of the world's first 'explicit open source' biotechnology toolkit.
Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
› Verified 3 days ago
| Entity Name | Affiliates Of Family Medicine Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609967678 PECOS PAC ID: 3779528005 Enrollment ID: O20050627000885 |
News Archive
Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has granted Ventana Medical Systems, Inc., a worldwide non-exclusive license to CST patent rights and proprietary antibody reagents relating to the detection of epidermal growth factor receptor mutations for the field of tissue-based in vitro diagnostic testing.
Valley Presbyterian Hospital was awarded a $772,643 grant from First 5 LA to implement the 'Welcome Baby' prenatal and infant care program. The grant period is from December 1, 2013 through June 30, 2014 and is expected to be extended for an additional year, through June 30, 2015.
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
In a publication in the scientific journal, Nature, a team at CAMBIA in Canberra unveils the 'kernel' of the world's first 'explicit open source' biotechnology toolkit.
Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elena Garcia, MD 503 Medical Center Blvd, Ste. 100, Conroe, TX 77304-2809 Ph: (936) 788-1060 | Elena Garcia, MD 503 Medical Center Blvd, Ste 100, Conroe, TX 77304-2809 Ph: (936) 788-1060 |
News Archive
Cell Signaling Technology, Inc. of Danvers, MA, announced today that it has granted Ventana Medical Systems, Inc., a worldwide non-exclusive license to CST patent rights and proprietary antibody reagents relating to the detection of epidermal growth factor receptor mutations for the field of tissue-based in vitro diagnostic testing.
Valley Presbyterian Hospital was awarded a $772,643 grant from First 5 LA to implement the 'Welcome Baby' prenatal and infant care program. The grant period is from December 1, 2013 through June 30, 2014 and is expected to be extended for an additional year, through June 30, 2015.
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).
In a publication in the scientific journal, Nature, a team at CAMBIA in Canberra unveils the 'kernel' of the world's first 'explicit open source' biotechnology toolkit.
Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
› Verified 3 days ago
Justin Grissom, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4015 I H 45 N Ste 100, Conroe, TX 77304 Phone: 936-270-4600 | |
Dr. Samantha Lorel Hinds-campa, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 690 S Loop 336 W, Ste 222, Conroe, TX 77304 Phone: 936-756-6661 Fax: 936-756-6681 | |
John Vernon Peet, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4015 I 45 N, Conroe, TX 77304 Phone: 936-760-7864 | |
Dr. Jason Biscamp, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 690 S Loop 336 W, 3rd Floor, Conroe, TX 77304 Phone: 936-522-4000 Fax: 936-522-4022 | |
Jody Ann Caldwell, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2510 S Loop 336 W, Suite 135, Conroe, TX 77304 Phone: 936-441-8999 | |
Dr. Victoria M Adeleye, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 508 Medical Center Blvd, Ste 200, Conroe, TX 77304 Phone: 936-760-4600 Fax: 936-760-4601 | |
William Patrick Mcdonough, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 605 S Conroe Medical Dr, Conroe, TX 77304 Phone: 936-539-4004 Fax: 936-521-3964 |